Answers are grounded in this paper and cite their sources.
Host lymphodepletion followed by autologous TIL transfer and IL-2 results in objective response rates of 50% to 70% in patients with metastatic melanoma refractory to standard therapies.
No takes yet. Share an insight, caveat, or question.
Dudley et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: